tiprankstipranks
Advertisement
Advertisement

ALEC Stock Latest News

Alector to discontinue PROGRESS-AD trial of nivisnebart
The FlyAlector to discontinue PROGRESS-AD trial of nivisnebart
2d ago
GSK
ALEC
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
16d ago
ALEC
Alector files $400M mixed securities shelf
PremiumThe Fly
Alector files $400M mixed securities shelf
2M ago
ALEC
BTIG upgrades Alector to Buy on shift to novel therapeutics
PremiumThe Fly
BTIG upgrades Alector to Buy on shift to novel therapeutics
2M ago
ALEC
Alector upgraded to Buy from Neutral at BTIG
PremiumThe Fly
Alector upgraded to Buy from Neutral at BTIG
2M ago
ALEC
Buy Rating on Alector: Strategic Pivot to Blood–Brain-Barrier Platform and Emerging Alzheimer’s Assets AL137 and AL064 Underpins Attractive Risk–Reward
PremiumRatingsBuy Rating on Alector: Strategic Pivot to Blood–Brain-Barrier Platform and Emerging Alzheimer’s Assets AL137 and AL064 Underpins Attractive Risk–Reward
2M ago
ALEC
Alector: Holding Amid Pipeline Setback as ABC Brain Delivery Platform Awaits Clinical Validation
Premium
Ratings
Alector: Holding Amid Pipeline Setback as ABC Brain Delivery Platform Awaits Clinical Validation
2M ago
ALEC
Alector reports Q4 EPS (34c), consensus (36c)
Premium
The Fly
Alector reports Q4 EPS (34c), consensus (36c)
2M ago
ALEC
Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
PremiumCompany Announcements
Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
3M ago
ALEC
Alector price target raised to 90c from 75c at Morgan Stanley
PremiumThe Fly
Alector price target raised to 90c from 75c at Morgan Stanley
4M ago
ALEC
Alector Appoints Neil Berkley as CFO
PremiumCompany Announcements
Alector Appoints Neil Berkley as CFO
5M ago
8K
ALEC
Alector names Neil Berkley as CFO, Chief Business Officer
PremiumThe Fly
Alector names Neil Berkley as CFO, Chief Business Officer
5M ago
ALEC
Cautious Outlook for Alector: Uncertainties in Clinical Validation and Financial Concerns Lead to Sell Rating
PremiumRatingsCautious Outlook for Alector: Uncertainties in Clinical Validation and Financial Concerns Lead to Sell Rating
5M ago
ALEC
Alector price target lowered to 75c from $1.50 at Morgan Stanley
Premium
The Fly
Alector price target lowered to 75c from $1.50 at Morgan Stanley
6M ago
ALEC
Alector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
Premium
Ratings
Alector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
6M ago
ALEC
Alector’s Strategic Shift to ABC Platform: Promising CNS Delivery and Neurodegenerative Disease Solutions
PremiumRatings
Alector’s Strategic Shift to ABC Platform: Promising CNS Delivery and Neurodegenerative Disease Solutions
6M ago
ALEC
Cautious Outlook on Alector Amid Strategic Shift and Uncertain Clinical Prospects
PremiumRatings
Cautious Outlook on Alector Amid Strategic Shift and Uncertain Clinical Prospects
6M ago
ALEC
Alector, Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Alector, Inc. Reports Q3 2025 Financial Results
6M ago
ALEC
Cautious Hold on Alector Amid Strategic Shift and Long-term Focus
PremiumRatings
Cautious Hold on Alector Amid Strategic Shift and Long-term Focus
6M ago
ALEC
Alector reports Q3 EPS (34c), consensus (41c)
PremiumThe FlyAlector reports Q3 EPS (34c), consensus (41c)
6M ago
ALEC
Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment
Premium
Company Announcements
Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment
6M ago
ALEC
Alector’s Strategic Potential in Biotechnology: Buy Rating Justified Despite Price Target Reduction
Premium
Ratings
Alector’s Strategic Potential in Biotechnology: Buy Rating Justified Despite Price Target Reduction
6M ago
ALEC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >